Rivoglitazone hydrochloride. PPARγ agonist, insulin sensitizer, treatment of diabetes

Drugs of the Future

Volumn 33, Issue 11, 2008, Pages 926-931

  Davies, S ^a   Castaner R ^a   Bolos J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BALAGLITAZONE; CI 1037; DE 101; GLITAZONE DERIVATIVE; GLUCOSE; ITRACONAZOLE; LOBEGLITAZONE; MOXIFLOXACIN; NETOGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; R 106056; RIVOGLITAZONE; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG COMPETITION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; EDEMA; FLUID RETENTION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL EDEMA; QT INTERVAL; SIDE EFFECT; WEIGHT GAIN;

EID: 60549094788     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.033.011.1278754     Document Type: Article

References (26)

1. Fujita, T., Wada, K., Oguchi, M. et al. (Daiichi Sankyo Co., Ltd.). Benzimidazole derivatives, their preparation and their therapeutic use. CA 2177858, EP 0745600, JP 1997295970, JP 2000001487, US 5886014.
2. Fujita, T., Izumi, T., Fujiwara, T. (Daiichi Sankyo Co., Ltd.). Hydrochloride of fused-heterocycle compound. EP 1180519, JP 2001039976, US 2002111373, US 6706746, WO 2000071540.
3. Kajino, H., Miyamoto, H., Ikeuchi, Y. (Sankyo Co., Ltd.). Intermediate of 6-substituted-1-methyl-1-H-benzimidazole derivative and method for producing same. CA 2580973, EP 1798216, JP 2006124375, WO 2006035685.
4. Nakamura, Y., Satoh, C., Miyamoto, H., Kajino, H. (Daiichi San kyo Co., Ltd.). Process for producing thiazolidinedione compound and production intermediate thereof. CA 2595782, EP 1894929, JP 2006225382, US 2008103185, WO 2006078037.
5. Kishi, N., Nakamura, Y., Abe, N., Takebayashi, T. (Sankyo Co., Ltd.). Intermediates for the synthesis of benzimidazole derivatives and a process for the preparation thereof. CA 2377233, EP 1191019, JP 2001072671, US 2003008907, US 2003199580, US 6525220, US 6753347, WO 2001000570.
6. Zimmet, P., Alberti, K.G., Shaw, J. Global and societal implications of the diabetes epidemic. Nature 201, 414(6865): 782-7.
7. Donnelly, R., Emslie-Smith, A.M., Gardner, I.D., Morris, A.D. ABC of arterial and venous disease: Vascular complications of diabetes. BMJ 2000, 320(7241): 1062-6.
8. Ferre, P. The biology of peroxisome proliferator-activated receptors: Relationship with lipid metabolism and insulin sensitivity. Diabetes 2004, 53(Suppl. 1): S43-50.
9. Leff, T., Mathews, S.T., Camp, H.S. Review: Peroxisome proliferator-activated receptor-gamma and its role in the development and treatment of diabetes. Exp Diabesity Res 2004, 5(2): 99-109.
10. Placebo and active comparator controlled dose response study of rivoglitazone in type 2 diabetes (RAISE) (NCT00575874). ClinicalTrials.gov Web site, November 10, 2008.
11. Placebo controlled dose-response study of rivoglitazone in type 2 diabetes (NCT00575471). ClinicalTrials.gov Web site, November 10, 2008.
12. Randomized, double-blind active comparator-controlled study of rivoglitazone in type 2 diabetes mellitus (NCT00484198). ClinicalTrials.gov Web site, November 10, 2008.
13. Placebo and active controlled study of rivoglitazone in type 2 diabetes (NCT00143520). ClinicalTrials.gov Web site, November 10, 2008.
14. Araki, K., Yachi, M., Hagisawa, Y. et al. Antidiabetic characterization of CS-011: A new thiazolidinedione with potent insulin-sensitizing activity. Diabetes [60th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 9-13, San Antonio) 2000] 2000, 49(Suppl. 1): Abst 425-P.
15. Ohsumi, J., Kanda, S., Matsui, Y. et al. Pharmacological characterization of rivoglitazone and its enatiomers in vitro and in vivo. 66th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 9-13, Washington, D.C.) 2006, Abst 2093-PO.
16. Ohsumi, J., Kanda, S., Tanaka, J. et al. Potent antidiabetic effects of rivoglitazone, a novel PPARγ agonist, in obese diabetic rodent models. 43rd Annu Meet Eur Assoc Study Diabetes (EASD) (Sept 17-21, Amsterdam) 2007, Abst 0854.
17. Kanda, S., Tanaka, J., Takahashi, K., Nakashima, R., Ohsumi, J. The effect of rivoglitazone (Rivo) on expression of genes targeted by PPARα and those implicated in cardiac function. Diabetes 2006, 55(Suppl. 1): Abst 2193-PO.
18. Pulaski, J.T., Davis, J.A., Yuille, K., Johnson, J.H. The antidiabetic effect of CI-1037/CS011, a new thiazolidinedione. Diabetes 2000, 49(Suppl. 1): Abst 496-P.
19. Walker, J.R., Triscari, J., Dmuchowski, C.F. et al. Single and multiple dose pharmacokinetics and pharmacodynamics of rivoglitazone (CS-011) in healthy male volunteers. 35th Annu Meet Am Coll Clin Pharmacol (ACCP) (Sept 17-19, Cambridge) 2006, Abst 37.
20. Walker, J.R., Yoshioka, S., Izumi, T. et al. A single-dose, food-effect and relative bioavailability study of tablet and oral formulations of rivoglitazone in healthy volunteers. J Clin Pharmacol 2008, 48(9): Abst 48.
21. Walker, J.R., Rohatagi, S., Salazar, D.E. et al. Thorough QTC study with rivoglitazone confirms no exposure-QTC response predicted by PK/PD modelling of pooled phase I/II ECG data. J Clin Pharmacol 2008, 48(9): Abst 49.
22. Triscari, J., Dmuchowski, C. The effects of rivoglitazone (PPARγ agonist) on adiponectin in healthy subjects. 66th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 9-13, Washington, D.C.) 2006, Abst 570-P.
23. Truitt, K., Chou, H.S., Wang, A., Walker, J.R., Rosenstock, J. A randomized, multiple-dose, placebo-controlled comparative study of rivoglitazone (Rivo, CS-011) and open-label pioglitazone (Pio) in patients with type 2 diabetes (T2DM). Diabetes [68th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 6-10, San Francisco) 2008] 2008, 57(Suppl. 1): Abst 437-P.
24. Triscari, J., Dmuchowski, C., Isaacsohn, J. Glucose levels in type 2 diabetes treated for 6 weeks with rivoglitazone HCI (CS-011). Diabetes 2006, 55(Suppl. 1): Abst 571-P.
25. Chou, H.S., Wang, A., Walker, J.R., Truitt, K., Rosenstock, J. A randomized, placebo-controlled, 26-week dose response study of rivoglitazone (RIVO, CS-011) versus pioglitazone (PIO) in patients with type 2 diabetes (T2DM). Diabetes [68th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 6-10, San Francisco) 2008] 2008, 57(Suppl. 1): Abst 304-OR.
26. Walker, J.R., Dmuchowski, C.F., Izumi, T., Samata, N., Mathew, P., Salazar, D.E. The steady-state pharmacokinetics of rivoglitazone (CS-011) are not affected by coadministration of the potent CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther [Annu Meet Am Soc Clin Pharmacol Ther (ASCPT) (March 21-24, Anaheim) 2007] 2007, 81(Suppl. 1): Abst Pl-84.